Latest Breaking News On - Wuxi biologics cayman - Page 8 : vimarsana.com
Didi Backer Temasek Optimistic on China Despite Regulatory Risk
msn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from msn.com Daily Mail and Mail on Sunday newspapers.
Didi Backer Temasek Optimistic on China Amid Tech Crackdown
msn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from msn.com Daily Mail and Mail on Sunday newspapers.
by Tyler Durden
Tuesday, Apr 27, 2021 - 07:46 AM
For the second day in a row, U.S. equity futures are starting the day barely changed, up just 0.1% and at new all time highs, alongside Treasury yields as earnings reports added to positive sentiment regarding an economic recovery in the developed world despite some disappointment in the latest TSLA results. The S&P 500 and the Nasdaq closed at record levels on Monday, with the tech-heavy Nasdaq completing a full recovery from its 11% correction that began in February.
At 07:15 a.m. ET, Dow E-minis were up 12 points, or 0.04%, S&P 500 E-minis were up 4.5 points or 0.1% to 4,184, trimming earlier gains that pushed the Emini as high as 4,192.5, and Nasdaq 100 E-minis were up 20 points, or 0.14%.
Apr 15, 2021
The call came early in the COVID-19 pandemic. Drew Weissman, an infectious diseases professor at the University of Pennsylvania and an expert in messenger RNA, received a query from a Chinese company interested in using the new technology to make a vaccine against the coronavirus.
The technology, which effectively turns the body’s cells into tiny vaccine-making factories, has since become the breakout star of the COVID-19 era, underpinning shots made by Moderna Inc. and the Pfizer Inc./BioNTech SE partnership which have been among the most effective in fighting the disease. Before the coronavirus hit, though, the experimental science had yet to receive regulatory approval for use against any illness let alone against the mysterious infection.
âI never heard from them againâ: A missed vaccine opportunity has left Chinese companies scrambling
Weâre sorry, this service is currently unavailable. Please try again later.
Dismiss
By Bruce Einhorn
Save
Normal text size
Advertisement
The call came early in the COVID-19 pandemic. Drew Weissman, an infectious diseases professor at the University of Pennsylvania and an expert in messenger RNA, received a query from a Chinese company interested in using the new technology to make a vaccine against the coronavirus.
mRNA, which effectively turns the bodyâs cells into tiny vaccine-making factories, has since become the breakout star of the COVID era, underpinning shots made by Moderna and the Pfizer/BioNTech partnership which have been among the most effective in fighting the disease. Before COVID hit, though, the experimental science had yet to receive regulatory approval for use against any illness - let alone against the mysterious respiratory infection.
vimarsana © 2020. All Rights Reserved.